SOLVO Biotechnology actively takes part in numerous Hungarian grants and European Framework Programs often as consortium leader. You can find below the list of ongoing and completed grants by sponsorship and scheme. We are continuously looking for new partners for upcoming grant applications. For further information, please contact us!
Ongoing Hungarian Grants
Ongoing EU Framework Programs (FP)
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP DILI) Call: IMI-JU-3rd call-2010-Topic 1 Contract number: 115336, Participant MIP DILI Project website: http://www.mip-dili.eu/
Completed Hungarian grants
French –Hungarian (NKTH-ANR) Bilateral Cooperation section Biotechnology 2009 Antimalarial drug discovery and development of new in vitro assays for the optimization of antimalaria therapy (ADDMAL09) Coordinator: SOLVO Biotechnology Partners: L’Universite Montpellier 2, L’ Universite Nice Sophia Antipolis, Institute Of Enzimology HAS BRC
National Technology Programme - 2008/1 Development of in vitro diagnostic test systems for predicting drug-resistance (IVDMDQ08) Coordinator: SOLVO Biotechnology Partners: University of Debrecen, Medical and Health Science Center; University of Pécs, Medical School; University of Szeged, Albert Szent-Györgyi Clinical Center; 77 Elektronika Ltd; T-Cell Technologies Ltd., Laboratory of Tumor Pathology and Molecular Diagnostics www.solvodiagnostics.com
Economic Development Operational Programme (with the support of the European Regional Development Fund) Development of innovative cell and membrane based assays for the detection of transporter interactions by a pharmacogenomic approach (GOP-1.1.1-11-2011-0064) The main objective of this project is the development and validation of novel methods for in-vitro testing of drug-transporter interactions. Moreover further development of experimental systems will result in new services and products (assay development and cell line generation). Coordinator: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.) Partners: HAS BRC Szeged, SeqOmics Kft., Mórahalom Further development and commecialization of SOLVO’s Predicell-uptake transzporter assay-kit product family (GOP-1.3.1-11/B-2011-0036) The main objectives of this project are to develop a living cell based, stabilized, transportable and ready-to-use in vitro testing device for the modelling of certain pharmacologic barriers and the detection of drug-transporter interactions) Beneficiary: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.) Integrated preclinical tools for the determination and the enhancement of drug absorption (GOP-1.1.1-11-2011-0017) The main objectives of this project are to develop new assays, to identify and validate a universal probe substrate for P-gp and BCRP and to validate our inverse prodrug approach aiming to enhance the absorption of certain drugs. Coordinator: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.) Partners: University of Debrecen Department of Organic Chemistry (address: H-4032, Hungary; Debrecen, Egyetem tér 1.) Enhancement of pharmacokinetic parameters of drugs with innovative multivalent conjugates (GOP-1.1.1-09/1-2009-0055) Poor oral bioavailability can be overcome by targeting transporter proteins present in the intestinal epithel with prodrug conjugates. The project will develop the capability to design, synthesize and test drug conjugates in this approach using the in vitro absorption model Caco-2 as well as transporter specific tools. Coordinator: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.) Partners: University of Szeged, Medical Faculty, Department of Medical Chemistry (address: H-6720 Szeged, Dóm tér 8.) Development of an in vivo technological platform for pharmaceutical applications by enhancing R&D capacities (GOP-1.3.2-09-2010-0008) The main objective of the project is to expand our current research methods with in vivo experimental systems for all the 4 physiological barriers (blood-brain barrier, kidney, liver, intestine) and cross-validate our in vitro systems with in vivo data obtained. Coordinator: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.)
Economic Development Operational Programme (with the support of the European Regional Development Fund) Extension of the IT system at Solvo Biotechnology (GOP-2011-2.1.1/A) The aim of the project is to modernize the current IT infrastructure at SOLVO Biotechnology Complex cell- and membrane vesicle based solution package development for high sensitivity pre-clinical screening of cholestethic compounds (GOP-1.1.1-09/1-2009-0054) Liver toxicity is a major hurdle in drug development and mourine in vivo models offer poor prediction. This project will develop an in vitro platform that aims good prediction of liver toxicity in man based on HepaRG cells as well as drug transporter containing membrane vesicles. Coordinator: SOLVO Biotechonology (address: H-6726 Szeged, Közép fasor 52.) Partners: Chemical Research Center Hungarian Academy of Sciences (address: H-1025 Budapest, Pusztaszeri út 59-67.) Improving the competitiveness of SOLVO Biotechnology by the implementation of an integrated enterprise resource planning (GOP-2.2.1-09/1-2010-0394) The aim of the project is to implement an integrated enterprise resource planning system (ERP) at SOLVO Biotechnology to improve the competitiveness of the company. In the frame of the project the currently used MS Navision 3.6 will be replaced. The new system enables comprehensive and extended support of the financial operations at SOLVO Biotechnology. Coordinator: SOLVO Biotechnology (address: H-6726 Szeged, Közép fasor 52.)
Péter Pázmány Programme Leading edge technologies in the Debrecen University Region: applications in genomics, nano- and biotechnologies (RET-06/2004) Coordinator: University of Debrecen Partners: National Instruments Europe Ltd.; Metalelektro Ltd.; Szinapszis Ltd.; Labexpert Ltd.; ACROM; Kéri Pharma; Papp-Ker Ltd.Mastergood Ltd.; Bakonszeg AWASSI; Juhker Ltd.; North Great Plain Regional Agricultural Innovation and Technology Transfer Centre Non-profit Company; SANATMETAL Manufacturer of Orthopaedic and Traumatologic Products; Comgenex Research and Development Inc.; SOLVO Biotechnology; Experimetria Ltd.; Synonens Research and Development Ltd.
Ányos Jedlik Programme Development of novel multi-target anti-inflammatory molecules using primary human phagocyte cellular assay systems (Inflamin) Coordinator: Vichem Chemie Research Ltd. Partners: Semmelweis University; Office for Academy Research Groups Attached to Universities, Peptide Biochemistry Research Group; SOLVO Biotechnology; University of Debrecen
László Kozma Programme Development of HTS kit for analyzing transporter-drug interactions using cholesterol treated insect-cells expressing human MXR transporter. Coordinator: SOLVO Biotechnology. Partners: none Oszkár Asbóth Programme - Focus Sector Innovation Program (FSIP) - 2005 Xenobiotic Transporter Technology Platform (XTTP) - Therapeutical and Toxicological Applications (XTTPSRT1) Coordinator: SOLVO Biotechonology Partners: University of Szeged; Biological Research Center of the Hungarian Academy of Science; Agricultural Biotechnological Research Centre; LAB Research International Hungary Ltd.; Avidin Ltd.
Oszkár Asbóth Programme - Focus Sector Innovation Program (FSIP) - 2005 DermaVir - Vaccine therapy innovation technological cluster (DermaVir) Coordinator: Chemical Research Center Hungarian Academy of Sciences Partners: ERCOM Ltd.; GENETIC IMMUNITY Kft.; Semmelweis University, Institute of Pathophysiology; University of Szeged; SOLVO Biotechnology; L&MARK Kft.; St. Laszlo Hospital
Péter Pázmány Program Neurobiological Knowledge Center - Therapeutic-Aimed neurobiological researches, from the molecule to the integrated functioning of the nervous systems (RET-08/2004) Coordinator: University of Szeged Partners: Biological Research Center of Szeged of the Hungarian Academy of Science; Hungarian Academy of Sciences Supported Research Groups; EGIS Pharmaceuticals; SOLVO Biotechnology; Diagnosticum Inc.; Kromat Ltd.; Creative Labor Ltd.; Rytmion R&D Ltd.; Kation Europe; QualiCont In Vitro Diagnostics; South-Plain Bioinnovation Center, Genomic Laboratory (DIABIC)
National Research and Development Programmes (NKFP) Investigation of cyclodextrin-cell membrane interactions to develop "second generation" cyclodextrins more efficient in drug formulation (NKFP-1A/041/2004) Coordinator: Cyclolab Research-Development Laboratory Ltd. Partners: Solvo Biotechnology; University of Debrecen; HAS- Institute of Enzimology; University of Szeged, Department of Medical Chemistry
Development of molecular therapeutic tools for pharmacological modulation of the effects of Progesterone Induced Blocking Factor (NKFP-1A/057/2004) Coordinator: Solvo Biotechnology Partners: University of Pécs, Faculty of Medicine Dept. Of Microbiology and Immunology; Biological Research Center of the Hungarian Academy of Science, Institute of Chemistry; Intercell Biomedical Research and Development AG; Semmelweis University Cooperative Research Centre, Rational Drug Design Laboratory; University of Szeged, Department of Medical Chemistry; University of Szeged, Faculty of Pharmacy, Dept. Pharmacodynamics and Biopharmacy; KPS Biotechnology Ltd.; L&Mark Informatika
Development and application of cell- and gene-therapy methods in medicine (NKFP-1A/060/2004) Coordinator: National Medical Center, Department of Hematology and Immunology Partners: HungAcadSci Institute of Experimental Medicine; Semmelweis University, Department of Surgery and Transplantion, First Department of Pediatric; HungAcadSci SzBK Institute of Enzimology, Economy and Biotechnology Research Center; Diagnostikum Ltd.; Solvo Biotechnology; MikroVákuum Ltd
Economic Competitiveness Operative Programme (EU Co-financed) Economic Competitiveness Operative Programme - 3.3.2- Development of Company Research Infrastructure Development of a novel biopharmacological and diagnostic methods (GVOP-3.3.2.-2004-04-0001/3.0) Coordinator: SOLVO Biotechnology
Economic Competitiveness Operative Programme - 3.1.1. - Applied Research & Development - 2004 Development of a new method based on PIBF measurement to diagnose malignant tumors and threatening abortion (GVOP-3.1.1.-2004-05-0329/3.0) Coordinator: University of Pécs Partners: SOLVO Biotechnology; Cooperative Research Center (SE)
In vitro pharmacokinetics; Development of high-through-put systems suitable for in vitro ADME-Tox investigations (vesicular-transport, ATP-ase and cellular model systems) (GVOP-3.1.1.-2004-05-0506/3.0) Coordinator: SOLVO Biotechnology Partners: HungAcadSci- Department of Enzimology, BRC
Development of cellular model systems expressing multidrug resistant proteins for the biological characterization of protein kinase inhibitors (GVOP-3.1.1.-2004-05-0467/3.0) Coordinator: Semmelweis University (Budapest) Partners: Cooperative Research Center (SE); National medical Center; Solvo Biotechnology; Vichem Chemie Ltd.
Development of in silico and in vitro methods for the prediction of multidrug resistance and penetration of blood-brain barrier (GVOP-3.1.1.-2004-05-0440/3.0) Coordinator: ComGenex Ltd. Partners: Solvo Biotechnology; University of Debrecen; ComGrid Ltd.
Multidrug Resistance Kit in rheumatoid arthritis (GVOP-3.1.1.-2004-05-0243/3.0) Coordinator: Semmelweis University (Budapest) Partners: County Hospital, Kecskemét; Solvo Biotechnology; Goodwill Research Ltd. Economic Competitiveness Operative Programme - 3.2.2. - Cooperative Research Centers - 2004 Establishment of the Human Biotechnological Research and Educational Center (GVOP-3.2.2.-2004-07-0015/3.0) Coordinator: National Medical Center Partners: Department of Medical Chemistry, Institute of Pathobiochemical and Molecular Biology, Semmelweis University; Department of Organic Chemistry, Eötvös Lóránd University of Science; Institute of Enzimology, Hungarian Academy of Sciences; Cytobiology Laboratory, Institute of Experimental Medical Science Research, Hungarian Academy of Sciences; Diagnosticum Ltd.; Solvo Biotechnology; Institute of Isotopes Co., Ltd.; Creative Development Deposit Company; GENOMED Ltd.; Csertex Ltd.; TRIGON Ltd.
Economic Competitiveness Operative Programme - 3.3.3 "Funding Company Innovation" Development of assay systems to study the interaction of test drugs with SLC uptake transporters (GVOP-3.3.3-05/1.-2005-05-0118/3.0) Beneficiary: Solvo Biotechnology
Economic Competitiveness Operative Programme - 3.3.2 - Development of Company Research Infrastructure Supporting research infrastructure for the development of assay systems to study the interaction of test drugs with SLC uptake transporters (GVOP-3.3.2-05/1.-2005-05-0015/3.0) Beneficiary: Solvo Biotechnology
Completed EUROSTARS Programs
Eustroke - European stroke research network Call: FP7-HEALTH-2007-A Instrument: CP-Large Scale Integration Project Contract number: HEALTH-F2-2008-202213 Eustroke on Cordis EUREKA Eurostars Programme Development of a Drug-transporter Specific Ready-to-use Monolayer Cell Product Line: PreadyPort Coordinator: SOLVO Biotechnology Partners: Advancell Advanced In vitro Cell Technologies SA
Completed EU Framework Programs (FP)
European Network to Promote Research into Uncommon Cancers in Adults and Children: Pathology, Biology and Genetics of Bone Tumors (“EuroBoNet”) Call: FP6-2004-LIFESCIHEALTH-5 Instrument: NoE Contract number: 018814, Participant Eurobonet on Cordis
EC Optimisation of liver and intestine in vitro models for pharmacokinetics and pharmacodynamics studies ("LIINTOP") Call: FP6-2005-LIFESCIHEALTH-6 Instrument: STREP Contract number: LSBH-CT-2006-037499, Co-PI Liintop on Cordis
Biosimulation- A New Tool in Drug Development ("BioSim") Call: FP6-2004-LIFESCIHEALTH Instrument: NoE Contract number: 005137, Co-PI Biosim on Cordis
Non-viral gene transfer ("INTHER") Call: FP6-2004-LIFESCIHEALTH-5 Instrument: STREP Contract number: LSBH-CT-2005-018961 Co-PI Inther on Cordis
Membrane transporters: In vitro models for the study of their role in drug fate ("MEMTRANS") Call: FP6-2004-LIFESCIHEALTH-5 Instrument: STREP Contract number: 518246, Co-PI Memtrans on Cordis
Towards new diagnostic standards - development of a protein based diagnostic assay and of a novel anti-abortion drug target (PIBF) Call: FP6-2003-SME-1 Instrument: CRAFT, Contract number: 018814COOP-CT-2004-508141 Pibf on Cordis
for a quote or for a meeting! Get in touch
for a quote or for a meeting! PrediGuide Transporter Guidance
- GOP-1.1.1-11-2011-0017 projekt
- GOP-1.1.1-11-2011-0064 projekt
- GOP-1.3.1-11/B-2011-0036 projekt
- GOP-1.3.2-09-2010-0008 Projekt
- GOP-1.1.1-09/1-2009-0054 projekt
- GOP-1.1.1-09/1-2009-0055 projekt